Diagnosis and management of herpes zoster by the family and community physician
DOI:
https://doi.org/10.5712/rbmfc9(32)994Keywords:
Herpes Zoster, Therapeutics, Primary Health CareAbstract
The herpes virus that causes varicella (chickenpox) persists in a latent form in the nervous system and can reactivate and propagate through nerve roots, manifesting years later through painful skin lesions, a condition called herpes zoster. The diagnosis is primarily clinical, but it is important to make a differential diagnosis with impetigo, contact dermatitis, dermatitis herpetiformis and also herpes simplex itself. After the diagnosis is confirmed, treatment should be initiated within the first 72 hours after onset of the rash and it is based upon antiviral therapy. Valacyclovir and famciclovir are more effective when compared to acyclovir. The most common complication of herpes zoster is post-herpetic neuralgia, usually managed with tricyclic antidepressants, anticonvulsants, topical lidocaine or capsaicin. Recently, a live attenuated vaccine against herpes zoster was introduced in Brazil, with the same components as the vaccine against varicella, but in a greater concentration. However, it still has a high cost and is not available in the public health system.
Downloads
Metrics
References
Portella AVT, Souza LCB, Gomes JMA. Herpes-zóster e neuralgia pós-herpética. Rev Dor. 2013;14(3):210-215. http://dx.doi.org/10.1590/S1806-00132013000300012. DOI: https://doi.org/10.1590/S1806-00132013000300012
Rimland D, Moanna A. Increasing incidence of herpes zoster among veterans. Clin Infect Dis. 2010;50(7):1000-1005. http://dx.doi.org/10.1086/651078. DOI: https://doi.org/10.1086/651078
Pinchinat S, Cebrián-Cuenca AM, et al. Similar herpes zoster incidence across Europe: results from a systematic review. BMC Infect Dis. 2013;13(170). http://dx.doi.org/10.1186/1471-2334-13-170. DOI: https://doi.org/10.1186/1471-2334-13-170
Cohen JI. Herpes Zoster. N Engl J Med. 2013;369(3):255-263. http://dx.doi.org/10.1056/NEJMcp1302674. DOI: https://doi.org/10.1056/NEJMcp1302674
Hayward AR, Herberger M. Lymphocyte responses to varicella zoster virus in the elderly. J Clin Immunol. 1987;7(2):174-178. http://dx.doi.org/10.1007/BF00916011. DOI: https://doi.org/10.1007/BF00916011
Hicks LD, Cook-Norris RH, Mendoza N, Madkan V, Arora A, Tyring SK. Family history as a risk factor for herpes zoster: a case-control study. Arch Dermatol. 2008;144(5):603-608. http://dx.doi.org/10.1001/archderm.144.5.603. DOI: https://doi.org/10.1001/archderm.144.5.603
Jong MD, Weel JFL, Oers MHJ, Boom R, Wertheim-van Dillen PME. Molecular diagnosis of visceral herpes zoster. The Lancet. 2001;357(9274):2101-2102. http://dx.doi.org/10.1016/S0140-6736(00)05199-0. DOI: https://doi.org/10.1016/S0140-6736(00)05199-0
Albrecht MA. Treatment of herpes zoster in the immunocompetent host. UpToDate. 2014 Jun.
Silva SF. Dermatology Atlas [Internet]. Herpes zoster. 2014 [acesso em 2014 Aug 19]. Disponível em: http://www.atlasdermatologico.com.br.
Degreef H. Famciclovir, a new oral antiherpes drug: results of the first controlled clinical study demonstrating its efficacy and safety in the treatment of uncomplicated herpes zoster in immunocompetent patients. Int J Antimicrob Agents. 1994;4(4):241-246. http://dx.doi.org/10.1016/0924-8579(94)90024-8. DOI: https://doi.org/10.1016/0924-8579(94)90024-8
Beutner KR, Friedman DJ, Forszpaniak C, Andersen PL, Wood MJ. Valaciclovir compared with acyclovir for improved therapy for herpes zoster in immunocompetent adults. Antimicrob Agents Chemother. 1995;39(7):1546-1553. http://dx.doi.org/10.1128/AAC.39.7.1546. DOI: https://doi.org/10.1128/AAC.39.7.1546
Tyring SK, Beutner KR, Tucker BA, Anderson WC, Crooks RJ. Antiviral therapy for herpes zoster: randomized, controlled clinical trial of valacyclovir and famciclovir therapy in immunocompetent patients 50 years and older. Arch Fam Med. 2000;9(9):863. http://dx.doi.org/10.1001/archfami.9.9.863. DOI: https://doi.org/10.1001/archfami.9.9.863
Chen N, Li Q, Yang J, Zhou M, Zhou D, He L. Antiviral treatment for preventing nerve pain after shingles (postherpetic neuralgia). Cochrane Database Syst Rev. 2014;(2). CD006866. http://dx.doi.org/10.1002/14651858.CD006866.pub3. DOI: https://doi.org/10.1002/14651858.CD006866.pub3
Li Q, Chen N, Yang J, Zhou M, Zhou D, Zhang Q, He L. Antiviral treatment for preventing postherpetic neuralgia. Cochrane Database Syst Rev. 2009;2(2). CD006866. http://dx.doi.org/10.1002/14651858.CD006866.pub2. DOI: https://doi.org/10.1002/14651858.CD006866.pub2
Whitley RJ, Weiss H, Gnann Jr JW, Tyring S, Mertz GJ, Pappas PG, et al. Acyclovir with and without prednisone for the treatment of herpes zoster: a randomized, placebo-controlled trial. Ann Intern Med. 1996;125(5):376-383. http://dx.doi.org/10.7326/0003-4819-125-5-199609010-00004. DOI: https://doi.org/10.7326/0003-4819-125-5-199609010-00004
Dubinsky RM, Kabbani H, El-Chami Z, Boutwell C, Ali H. Practice parameter: treatment of postherpetic neuralgia: an evidence-based report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology. 2004 Sep 28;63(6):959-65 (reaffirmed Feb 2008). htpp://dx.doi.org/10.1212/01.WNL.0000140708.62856.72. DOI: https://doi.org/10.1212/01.WNL.0000140708.62856.72
Oxman MN, Levin MJ, Johnson GR, Schmader KE, Straus SE, Gelb LD, et al. A vaccine to prevent herpes zoster and postherpetic neuralgia in older adults. N Engl J Med. 2005;352(22):2271-2284. http://dx.doi.org/10.1056/NEJMoa051016. DOI: https://doi.org/10.1056/NEJMoa051016
Fashner J, Bell LA. Herpes Zoster and postherpetic neuralgia: prevention and management. Am Fam Physician. 2011;83(12):1432-1437.
Downloads
Published
How to Cite
Issue
Section
License
By submitting a manuscript to the RBMFC, authors retain ownership of the copyright in the article, and authorize RBMFC to publish that manuscript under the Creative Commons Attribution 4.0 license and identify itself as the vehicle of its original publication.